In addition to the reported results of Abbott Vascular’s bioresorbable stent (which Felix Lee, M.D., will report on separately), five late-breaking trials caught my attention at the American College of Cardiology’s 2017 meeting in Washington, D.C., which will also be of interest to many HealthTrust member facilities. A summary of these studies and the implications […]
The annual Transcatheter Cardiovascular Therapeutics conference featured scientific presentations that highlighted clinical approaches no better and no worse than the alternatives, although in the ILLUMENATE Pivotal Trial a novel paclitaxel-coated balloon was found to be superior to routine percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial disease. Scientific presentations and educational sessions at this […]
Compelling evidence was presented at ESC 2016 supporting the use of implantable cardioverter defibrillators in heart failure patients, continuous positive airway pressure to improve patient quality of life, drug-eluting stents in reducing the need for repeat revascularizations, and stem cell therapy for patients with severe heart enlargement.